Red and near-infrared photobiomodulation may influence mitochondrial, redox, nitric-oxide, calcium, and inflammatory signaling, but clinical evidence for autoimmune diseases remains limited and condition-specific. The article reviews safety, dosing, regulatory documentation, and REDDOT LED's 37-step inspection, emphasizing that PBM is investigational and should complement—not replace—medical care.

Lupus patients frequently inquire whether red light therapy is safe (given their photosensitivity), how it interacts with hydroxychloroquine, and whether it can alleviate joint pain or fatigue. Although the wavelengths of red and near-infrared light fall outside the ultraviolet spectrum known to trigger lupus flares, there are currently no clinical trials specifically addressing Systemic Lupus Erythematosus (SLE); therefore, consulting a physician remains essential.

Red light therapy may support autoimmune care by reducing inflammation, oxidative stress, and mitochondrial dysfunction. Evidence is strongest for rheumatoid arthritis and psoriasis, while lupus, MS, and IBD data remain limited. It should be used conservatively, with medical guidance, as a complement—not a replacement—for prescribed treatment.